VaxInnate Licenses Recombinant Flu Vaccines To South Korea’s CJ CheilJedang Corp

VaxInnate Corporation has granted CJ CheilJedang Corporation an exclusive license to manufacture, develop, and commercialize its recombinant seasonal and pandemic flu vaccines in South Korea.

AsianScientist (Dec. 19, 2011) – VaxInnate Corporation announced today that it has granted CJ CheilJedang Corporation an exclusive license to manufacture, develop, and commercialize its recombinant seasonal and pandemic flu vaccines in South Korea.

CJ CheilJedang is a leading provider of drugs and vaccines to private and public markets in South Korea through CJ Pharma, the company’s biopharmaceutical arm.

The agreement also includes a non-exclusive license to market the vaccines in certain Southeast Asian countries, excluding China. Under the terms of the agreement, CJ CheilJedang Corporation will be responsible for funding clinical development and licensure of the vaccine in South Korea and ten other Southeast Asian countries.

VaxInnate will transfer the technology required to develop and manufacture the vaccines. Financial terms of the agreement include an upfront fee, clinical and regulatory milestone payments, and royalties on sales.

As with all new vaccines, the Korean and other governments must grant marketing approval based upon clinical evaluation before they can be used.

“Collaboration with VaxInnate will be a cornerstone for CJ’s flu vaccine business,” said Seok-Hee Kang, Senior Executive VP and Head of Pharmaceutical Business of CJ CheilJedang.

“We believe that the TLR technology of VaxInnate is very competitive in vaccine development and it will place CJ in a superior position in the flu vaccine market.”

Meanwhile, VaxInnate plans to pursue clinical development and licensure of its seasonal and pandemic vaccines in the United States, Europe, and other regions.

Headquartered in Cranbury, New Jersey, VaxInnate develops vaccines for seasonal and pandemic flu, dengue, and malaria based upon recombinant expression of fusion molecules that combine the vaccine antigen with a potent immune stimulator, the toll-like receptor 5 (TLR 5) agonist, flagellin.

According to VaxInnate, its technology makes it possible to produce hundreds of millions of vaccine doses in as little as three to four months during a pandemic flu outbreak, significantly faster than by using either eggs or cell culture.

——

Source: VaxInnate Corporation.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist